SI

SI is a preclinical-stage small molecule drug candidate being developed by JW Pharmaceuticals for the treatment of various immune and inflammatory diseases. It is part of the company's proprietary STAT3 inhibitor program, which utilizes a specialized drug discovery platform to identify small molecules that target the SH2 domain of the STAT3 (Signal Transducer and Activator of Transcription 3) protein. By inhibiting the phosphorylation and dimerization of STAT3, the drug blocks the signaling of multiple pro-inflammatory cytokines, such as IL-6, IL-17, and IL-23, which are key drivers of autoimmune pathology. Unlike many existing therapies that target single cytokines, SI's inhibition of the downstream STAT3 transcription factor offers a broader potential to modulate complex immune responses. The program is currently in the preclinical phase, with JW Pharmaceuticals exploring its efficacy in conditions such as atopic dermatitis and other inflammatory disorders.

Other names

STAT3 inhibitorSTAT-3 inhibitorSTAT 3 inhibitor